These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34911167)

  • 1. The omicron variant of SARS-CoV-2: Understanding the known and living with unknowns.
    Ingraham NE; Ingbar DH
    Clin Transl Med; 2021 Dec; 11(12):e685. PubMed ID: 34911167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent insights into SARS-CoV-2 omicron variant.
    Silva SJRD; Kohl A; Pena L; Pardee K
    Rev Med Virol; 2023 Jan; 33(1):e2373. PubMed ID: 35662313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
    Wang R; Chen J; Gao K; Wei GW
    Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.
    Wolf JM; Wolf LM; Bello GL; Maccari JG; Nasi LA
    J Med Virol; 2023 Jan; 95(1):e28366. PubMed ID: 36458547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Omicron the last SARS-CoV-2 Variant of Concern?
    Rahimi F; Talebi Bezmin Abadi A
    Arch Med Res; 2022 Apr; 53(3):336-338. PubMed ID: 35093242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa.
    Wang L; Cheng G
    J Med Virol; 2022 Apr; 94(4):1728-1733. PubMed ID: 34897752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
    CDC COVID-19 Response Team
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(50):1731-1734. PubMed ID: 34914670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heavily mutated Omicron variant puts scientists on alert.
    Callaway E
    Nature; 2021 Dec; 600(7887):21. PubMed ID: 34824381
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2.
    Antony P; Jobe A; Vijayan R
    PeerJ; 2022; 10():e13680. PubMed ID: 35811809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.
    Meo SA; Meo AS; Al-Jassir FF; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8012-8018. PubMed ID: 34982465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2022 Feb; 28():e936199. PubMed ID: 35102132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
    Dhama K; Nainu F; Frediansyah A; Yatoo MI; Mohapatra RK; Chakraborty S; Zhou H; Islam MR; Mamada SS; Kusuma HI; Rabaan AA; Alhumaid S; Mutair AA; Iqhrammullah M; Al-Tawfiq JA; Mohaini MA; Alsalman AJ; Tuli HS; Chakraborty C; Harapan H
    J Infect Public Health; 2023 Jan; 16(1):4-14. PubMed ID: 36446204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron: a drug developer's perspective.
    Fang FF; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):208-211. PubMed ID: 34951568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of Omicron Variant at the Interface of the Receptor Domain Motif and Human Angiotensin-Converting Enzyme-2.
    Adhikari P; Jawad B; Podgornik R; Ching WY
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
    Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
    Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.